Postprandial glucose regulation: New data andnew implications

Clinical Therapeutics

Volumn 27, Issue SUPPL. 2, 2005, Pages

  Leiter, Lawrence A ^a   Ceriello, Antonio ^b   Davidson, Jaime A ^c   Hanefeld, Markolf ^d   Monnier, Louis ^e   Owens, David R ^f   Tajima, Naoko ^g   Tuomilehto, Jaakko ^h  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF UDINE   (Italy)

^c MEDICAL CITY DALLAS HOSPITAL   (United States)

^d DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^e UNIV MONTPELLIER   (France)

^f CARDIFF UNIVERSITY   (United Kingdom)

^g JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

cardiovascular disease; postprandial glucose; postprandial hyperglycemia; type 2 diabetes

Indexed keywords

ACARBOSE; ADVANCED GLYCATION END PRODUCT; BIPHASIC INSULIN; C REACTIVE PROTEIN; CITRIC ACID; GLIBENCLAMIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN ASPART; INSULIN GLARGINE; ISOPHANE INSULIN; REPAGLINIDE; TRIACYLGLYCEROL; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; GLYCOSYLATED HEMOGLOBIN;

ARTERY INTIMA PROLIFERATION; ARTICLE; CARDIOVASCULAR DISEASE; CITRIC ACID CYCLE; CORONARY ARTERY DISEASE; CORRELATION COEFFICIENT; DIABETES CONTROL; DIABETIC MICROANGIOPATHY; DIABETIC PATIENT; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; DOSE CALCULATION; DRUG EFFICACY; ENDOTHELIAL DYSFUNCTION; GLUCOSE BLOOD LEVEL; HEART PROTECTION; HEMOGLOBIN DETERMINATION; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INFORMATION RETRIEVAL; MEDICAL ASSESSMENT; MEDICAL LITERATURE; MEDLINE; NEUROLOGIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; OUTPATIENT DEPARTMENT; OXIDATIVE STRESS; PATHOPHYSIOLOGY; POSTPRANDIAL STATE; PREGNANCY DIABETES MELLITUS; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; TRIACYLGLYCEROL BLOOD LEVEL; ATHEROSCLEROSIS; BLOOD; CLINICAL TRIAL; DIABETIC ANGIOPATHY; METABOLISM; PHYSIOLOGY; REVIEW;

ATHEROSCLEROSIS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; CLINICAL TRIALS; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; POSTPRANDIAL PERIOD;

EID: 33644932611     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2005.11.020     Document Type: Article

References (60)

1. Monnier L., Lapinski H., and Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: Variations with increasing levels of HbA(1c). Diabetes Care 26 (2003) 881-885
2. El-Kebbi I.M., Ziemer D.C., Cook C.B., et al. Utility of casual postprandial glucose levels in type 2 diabetes management. Diabetes Care 27 (2004) 335-339
3. Siebenhofer A., Plank J., Berghold A., et al. Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. Cochrane Database Syst Rev 4 (2004) CD003287
4. Raskin P., Allen E., Hollander P., et al., INITIATE Study Group. Initiating insulin therapy in type 2 diabetes: A comparison of biphasic and basal insulin analogues. Diabetes Care 28 (2005) 260-265
5. Christiansen J.S., Vaz J.A., Metelko Z., et al. Twice daily biphasic insulin aspart improves postprandial glycaemic control more effectively than twice daily NPH insulin, with low risk ofhypoglycaemia, in patients with type 2 diabetes. Diabetes Obes Metab 5 (2003) 446-454
6. Ceriello A., Quagliaro L., Catone B., et al. Role of hyperglycemia in nitrotyrosine postprandial generation. Diabetes Care 25 (2002) 1439-1443
7. Ceriello A., Cavarape A., Martinelli L., et al. The post-prandial state in type 2 diabetes and endothelial dysfunction: Effects of insulin aspart. Diabet Med 21 (2004) 171-175
8. Beisswenger P.J., Howell S.K., O'Dell R.M., et al. Alpha-dicarbonyls increase in the postprandial period and reflect the degree of hyperglycemia. Diabetes Care 24 (2001) 726-732
9. Esposito K., Giugliano D., Nappo F., Marfella R., and Campanian Postprandial Hyperglycemia Study Group. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation 110 (2004) 214-219
10. Hanefeld M., Chiasson J.L., Koehler C., et al. Acarbose slows progression of intima-media thickness ofthe carotid arteries in subjects with impaired glucose tolerance. Stroke 35 (2004) 1073-1078
11. Chiasson J.L., Josse R.G., Gomis R., et al., STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: The STOP-NIDDM trial. JAMA 290 (2003) 486-494
12. Hanefeld M., Cagatay M., Petrowitsch T., et al. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: Meta-analysis of seven long-term studies. Eur Heart J. 25 (2004) 10-16
13. The Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe (DECODE) Study Group, and European Diabetes Epidemiology Group. Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases?. Diabetes Care 26 (2003) 688-696
14. Harris M.I. Undiagnosed NIDDM: Clinical and public health issues. Diabetes Care 16 (1993) 642-652
15. Krolewski A.S., Laffel L.M., Krolewski M., et al. Glycosylated hemoglobin and the risk of microalbuminuria in patients with insulin-dependent diabetes mellitus. N Engl J Med 332 (1995) 251-1255
16. American Diabetes Association. Standards of medical care. Diabetes Care 28 Suppl 1 (2005) 54-536
17. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report ofthe Expert Committee on the Diagnosis and Classification ofDiabetes Mellitus. Diabetes Care 20 (1997) 1183-1197
18. American Diabetes Association. Postprandial blood glucose. Diabetes Care 24 (2001) 775-778
19. Kannel W.B., and McGee D.L. Diabetes and cardiovascular disease. The Framingham Study. JAMA 241 (1979) 2035-2038
20. Kuusisto J., Mykkanen L., Pyorala K., and Laakso M. NIDDM and its metabolic control predict coronary heart dis ease in elderly subjects. Diabetes 43 (1994) 960-967
21. Stratton I.M., Adler A.I., Neil H.A., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ 321 (2000) 405-412
22. [published correction appears in Lancet. 1999;354:602]. UK Prospective Diabetes Study (UKPDS) Group. Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
23. de Backer G., Ambrosioni E., Borch- J.K., et al. European guidelines on cardiovascular disease preven tion in the clinical practice. Third work group of the European societies and other societies on cardiovascular disease prevention in the clinical practice [in Spanish]. Neurologia 19 (2004) 440-450
24. Available at [eh][ir]www.diabetes.ca/cpg2003. Canadian Diabetes Association. Clinical practice guidelines for the prevention and management of diabetes in Canada. Accessed August 26, 2005 (2003)
25. American College of Endocrinology. Consensus statement on guidelines for glycemic control. Endocr Pract 8 Suppl 1 (2002) 5-11
26. Meigs J.B., Nathan D.M., D'Agostino Sr. R.B., and Wilson P.W. Framingham Offspring Study. Fasting and post challenge glycemia and cardiovascular disease risk: The Framingham Offspring Study. Diabetes Care 25 (2002) 1845-1850
27. The Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe (DECODE) Study Group, and European Diabetes Epidemiology Group. Glucose tolerance and mortality: Comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 354 (1999) 617-621
28. Tominaga M., Eguchi H., Manaka H., et al., The Funagata Diabetes Study. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. Diabetes Care 22 (1999) 920-924
29. Qiao Q., Nakagami T., Tuomilehto J., et al., International Diabetes Epidemiology Group, DECODA Study Group. Comparison of the fasting and the 2-h glucose criteria for diabetes in different Asian cohorts. Diabetologia 43 (2000) 1470-1475
30. Woerle H.J., Pimenta W.P., Meyer C., et al. Diagnostic and therapeutic implications of relationships between fasting, 2-hour postchallenge plasma glucose and hemoglobin a1c values. Arch Intern Med 164 (2004) 1627-1632
31. Ceriello A. New insights on oxidative stress and diabetic complications may lead to a "causal" antioxidant therapy. Diabetes Care 26 (2003) 1589-1596
32. Ceriello A., Hanefeld M., Leiter L., et al. Postprandial glucose regulation and diabetic complications. Arch Intern Med 164 (2004) 2090-2095
33. Maddux B.A., See W., Lawrence Jr. J.C., et al. Protection against oxidative stress-induced insulin resistance in rat L6 muscle cells by micromolar concentrations of alpha-lipoic acid. Diabetes 50 (2001) 404-410
34. Ceriello A., and Motz E. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arterioscler Thromb Vasc Biol 24 (2004) 816-823
35. Perticone F., Ceravolo R., Pujia A., et al. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation 104 (2001) 191-196
36. [published correction appears in Circulation. 2003;108:500]. Heitzer T., Schlinzig T., Krohn K., et al. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 104 (2001) 2673-2678
37. Kawano H., Motoyama T., Hirashima O., et al. Hyperglycemia rapidly suppresses flow-mediated endothelium dependent vasodilation of brachial artery. J Am Coll Cardiol 34 (1999) 146-154
38. Giugliano D., Marfella R., Coppola L., et al. Vascular effects of acute hyperglycemia in humans are reversed by l-arginine. Evidence for reduced availability of nitric oxide during hyperglycemia. Circulation 95 (1997) 1783-1790
39. Ceriello A., Taboga C., Tonutti L., et al. Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidativestress generation: Effects of short- and long-term simvastatin treatment. Circulation 106 (2002) 1211-1218
40. Marfella R., Verrazzo G., Acampora R., et al. Glutathione reverses systemic hemodynamic changes induced by acute hyperglycemia in healthy subjects. Am J Physiol 268 (1995) E1167-E1173
41. Ting H.H., Timimi F.K., Boles K.S., et al. Vitamin C improves endothelium-dependent vasodilation in patientswith non-insulin-dependent diabetes mellitus. J Clin Invest 97 (1996) 22-28
42. Ceriello A., Quagliaro L., D'Amico M., et al. Acute hyperglycemia induces nitrotyrosine formation and apoptosis in perfused heart from rat. Diabetes 51 (2002) 1076-1082
43. Ceriello A., Bortolotti N., Motz E., et al. Meal-induced oxidative stress and low-density lipoprotein oxida tion in diabetes: The possible role of hyperglycemia. Metabolism 48 (1999) 1503-1508
44. Beisswenger P.J., Makita Z., Curphey T.J., et al. Formation of immunochemical advanced glycosylation end products precedes and correlates with early manifestations of renal and retinal disease indiabetes. Diabetes 44 (1995) 824-829
45. Beisswenger P.J., Szwergold B.S., and Yeo K.T. Glycated proteins in diabetes. Clin Lab Med 21 (2001) 53-78
46. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 414 (2001) 813-820
47. [published correction appears in Diabetes. 2003;52:1307]. Schiekofer S., Andrassy M., Chen J., et al. Acute hyperglycemia causes intracellular formation of CIVIL and activation of ras, p42/44 MAPK, and nuclear factor kappap in PBMCs. Diabetes 52 (2003) 621-633
48. McLellan A.C., Thornalley P.J., Benn J., and Sonksen P.H. Glyoxalase system in clinical diabetes mellitus and corre lation with diabetic complications. Clin Sci (Loud) 87 (1994) 21-29
49. Temelkova-Kurktschiev T.S., Koehler C., Henkel E., et al. Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level. Diabetes Care 23 (2000) 1830-1834
50. Sasso F.C., Carbonara O., Nasti R., et al. Glucose metabolism and coronary heart disease in patients with nor mal glucose tolerance. JAMA 291 (2004) 1857-1863
51. Nakamura N., Ueno Y., Tsuchiyama Y., et al. Isolated post-challenge hyperglycemia in patients with normal fasting glucose concentration exaggerates neointimal hyperplasia after coronary stentimplantation. Circ J. 67 (2003) 61-67
52. Ohshita K., Yamane K., Ishida K., et al. Post-challenge hyperglycaemia is an independent risk factor for arterial stiffness in Japanese men. Diabet Med 21 (2004) 636-639
53. de Veciana M., Major C.A., Morgan M.A., et al. Postprandial versus preprandial blood glucose monitoring in women with gestational diabetes mellitus requiring insulin therapy. N Engl J Med 333 (1995) 1237-1241
54. Rudofsky Jr. G., Reismann P., Schiekofer S., et al. Reduction of postprandial hyperglycemia in patients with type2 diabetes reduces NF-kappap activation in PBMCs. Horm Metab Res 36 (2004) 630-638
55. Ridker P.M., Rifai N., Stampfer M.J., and Hennekens C.H. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 101 (2000) 1767-1772
56. Blankenberg S., Tiret L., Bickel C., et al., AtheroGene Investigators. Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation 106 (2002) 24-30
57. Hashimoto H., Kitagawa K., Hougaku H., et al. Relationship between Creactive protein and progression of early carotid atherosclerosis in hypertensive subjects. Stroke 35 (2004) 1625-1630
58. Introduction. American Diabetes Association. Clinical practice recommendations 2003. Diabetes Care 26 Suppl 1 (2003) S1-S2
59. Coutinho M., Gerstein H.C., Wang Y., and Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 22 (1999) 233-240
60. Monnier L., Colette C., and Lapinski H. Global assessment for quality and safety of control in type 2 diabetic patients. Eur J Clin Invest 34 (2004) 37-42